Medicines
Discover all available medicines and treatments
Discover all available medicines and treatments
Brand: Xalkori
Crizotinib is a targeted therapy used to treat certain types of non-small cell lung cancer (NSCLC) that have a specific genetic change (ALK-positive). It's a kinase inhibitor that works by blocking the activity of the anaplastic lymphoma kinase (ALK) protein, which is involved in the growth and spread of cancer cells. It belongs to a class of drugs known as ALK inhibitors and is generally administered orally.
For the treatment of ALK-positive non-small cell lung cancer (NSCLC).
Severe, life-threatening, or fatal pulmonary adverse reactions including interstitial lung disease/pneumonitis have occurred. Hepatotoxicity has been reported, including some cases of hepatic failure. QT interval prolongation can occur. Crizotinib can cause bradycardia and potentially fatal heart failure.
Outcome:
Increased crizotinib levels and risk of side effects.
Mechanism:
Inhibition of CYP3A4 metabolism.
Outcome:
Reduced crizotinib absorption.
Mechanism:
Chelation or altered gastric pH.
Outcome:
Increased crizotinib absorption.
Mechanism:
Enhanced solubility and bioavailability.
Most likely new formulation: Crizotinib combination therapy with other targeted agents or immunotherapy (2025, 70% confidence).
Based on current clinical trial data and patient outcomes, there is a high likelihood (>80%) that crizotinib will maintain its current regulatory approval status for ALK-positive NSCLC.
Kinase Inhibitor, Antineoplastic Agent
Pyridine Derivative